Kermode

Kermode Biotechnologies is a preclinical-stage biotechnology company developing a new class of broad-spectrum antiviral therapeutics designed to address current and emerging viral threats. The company's platform focuses on targeting conserved glycans on the surface of viral envelopes, which are essential for viral entry and immune evasion across diverse viral families. This approach allows for the development of universal treatments effective against multiple strains of viruses, including influenza, coronaviruses, and filoviruses. By focusing on these invariant targets, Kermode's candidates are engineered to be resistant to the rapid mutations that typically render traditional vaccines and antivirals ineffective. The company aims to provide a critical tool for pandemic preparedness and the management of seasonal viral outbreaks through a one-drug, many-bugs strategy.